You are here: Home » International » News » Companies
Business Standard

Sanofi offers to buy Dutch biotechnology firm Kiadis for $358.4 million

Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells

Sanofi  | Biotechnology


Logo of French drugmaker Sanofi | Photo: Reuters
Photo: Reuters

is offering to buy Dutch company Kiadis for 308 million euros ($358.4 million) to boost its range of immunotherapy products.

The French drugmaker will offer 5.45 euros in cash, the said in a joint statement on Monday, a premium of 272% to Kiadis' closing share price on Oct. 30.

Shares in Kiadis, focused on cell-based immunotherapy products for the treatment of cancer, were up 245% in early trading. shares were up 1.18%.

Kiadis owns a platform based on a so-called "allogeneic natural killer" that can seek and identify malignant cancer cells.

"We believe Kiadis 'off the shelf' K-NK cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi's immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches," said John Reed, global head of research and development at

The deal is the latest in a series of bolt-on transactions for Sanofi. In August, it spent $3.7 billion to buy U.S. autoimmune diseases specialist Principia Biopharma following a $2.5 billion investment to acquire immuno-oncology treatments group Synthorx in December last year.

Sanofi was late to capitalise on the takeoff of immunotherapy - drugs that activate the body’s immune system to attack tumor cells - in the early 2010s.

It is now trying to catch up and is focusing on a pipeline of several medicines that it hopes will secure it a piece of the $100 billion-a-year cancer drug market.

Sanofi said Kiadis' medicines will be developed alone and in combination with Sanofi's existing platforms.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, November 03 2020. 02:00 IST